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httpSuperﬁcialization of brachial artery as effective
alternative vascular access
Takashi Nakamura, MD,a Kotaro Suemitsu, MD,b and Junichi Nakamura, MD,c Osaka, Japan
Objective: The Japanese Society for Dialysis Therapy recommends superﬁcialization of the brachial artery (BA) as an
alternative vascular access (VA) technique in patients for whom a conventional internal shunt (arteriovenous ﬁstula
[AVF] or arteriovenous graft) cannot be created. Although 2% to 3% of Japanese hemodialysis patients undergo this
procedure, it is not well recognized worldwide. We report here our experience with the procedure, as well as indications,
durability, and morbidity.
Methods: The technique involves exposure of the BA and ligation of the side branches, then ﬁxing it beneath the skin at the
upper arm. Cannulation of the BA is performed 2 weeks or more after surgery, and it is used as an outﬂow route, with any
vein in an upper extremity utilized for blood return, including the hand if sites in the arm are not accessible. We
retrospectively reviewed our cases of superﬁcialization of the BA for VA.
Results: From 2005 through 2008, a total of 24 patients (11 females [46%]; average age, 69 years [range, 39-84 years])
underwent superﬁcialization of the BA, of whom eight (33%) had diabetes. The indications were (1) impaired cardiac
function (n [ 13); (2) no other prospect for AVF or patient refused prosthetic graft implantation (n [ 5); (3) severe
upper extremity arterial disease or ischemic steal syndrome requiring AVF closure (n[ 3); (4) venous hypertension with
central vein occlusion (n[ 2); and (5) repeated AVF thrombosis due to heparin-induced thrombocytopenia (n[ 1). The
mean follow-up period was 28 months. Serious complications were seen in one patient with an infected pseudoaneurysm
formation associated with a BA puncture, which necessitated BA ligation, while two patients required an aneurysmectomy
with reconstruction and one had occlusion of the superﬁcialized BA, though no clinical symptoms of hand ischemia
developed. We also had difﬁculty ﬁnding a vein for blood return in ﬁve patients. The rate of superﬁcialized BA patency as
a functioning VA was 95% and 66% at 1 and 3 years, respectively.
Conclusions: Superﬁcialization of the BA was found to be a simple and safe technique, with acceptable durability and
complication rate in selected Japanese hemodialysis patients. We consider that this shuntless VA permits adequate blood
ﬂow and has theoretical advantages for some patients, particularly those with impaired cardiac function, though the
availability of a return vein is a prerequisite for a functioning VA. (J Vasc Surg 2014;59:1385-92.)A well-functioning vascular access (VA) is essential for
efﬁcient hemodialysis therapy, with several guidelines for
better care presented. An autogenous arteriovenous ﬁstula
(AVF) is the most preferred method for a VA in terms of
durability, complications, and total cost of maintenance
as compared to a prosthetic arteriovenous graft (AVG) or
central venous catheter.1-6 Over 90% of such patients
treated in Japan receive hemodialysis with an AVF, while
an AVG is used in 7% and a permanent catheter in less
than 2%.7 However, there has been an increase in patients
with comorbid conditions, including severe heart failure
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://dx.doi.org/10.1016/j.jvs.2013.11.093difﬁcult to create a conventional AVF or AVG. The Japa-
nese Society for Dialysis Therapy published guidelines for
VA in 2005 and revised them in 2011.6,8 They recommend
artery superﬁcialization, including the brachial artery (BA)
and femoral artery (FA), as an alternative VA technique for
patients in whom a conventional AVF or AVG cannot be
created, such as those with concomitant heart failure,
VA-related severe ischemic steal syndrome, or venous hy-
pertension with central vein occlusion. Although 2% to
3% of Japanese hemodialysis patients undergo this method,
it is not recognized worldwide. We report here our experi-
ence with the procedure, as well as indications, durability,
and morbidity.
METHODS
We reviewed our database of patients who underwent
superﬁcialization of the BA between January 2005 and
December 2008. All of the operations were performed
at a single hospital-based VA center in Osaka on an outpa-
tient basis. Baseline demographic information as well as pa-
tient and VA characteristics were retrieved from clinical
notes and the hospital electronic database. All complica-
tions, including pseudoaneurysm, thrombosis, infection,
and ischemia, as well as subsequent treatments, were
recorded. Primary outcome measures were patency of the
BA as a functional VA following superﬁcialization and pa-
tient survival. Functional VA patency was deﬁned as a1385
Fig 1. Details of the procedure. A, Hockey stick-shaped skin incision. B, Creation of skin ﬂap. C, The brachial artery
(BA) is isolated from its branches and subcutaneous tissue beneath the BA is sutured for superﬁcialization. D, The skin
ﬂap is closed with interrupted sutures.
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turn site was accessible. The indications for this procedure
were based on the recommendations of The Japanese Soci-
ety for Dialysis Therapy, with the following exclusion
criteria: (1) no suitable vein for blood return; (2) BA
diameter <3.0 mm; (3) circumferential calciﬁcation seen
in X-ray images; (4) severe obesity; and (5) lack of patient
agreement and/or poor patient cooperation. In addition to
a physical examination, a preoperative ultrasound examina-
tion with a tourniquet placed was performed for all patients
to verify robust veins for return sites, while the diameter,
degree of atherosclerosis and calciﬁcation, and depth
from the skin of the BA were also evaluated. No other im-
aging studies such as angiography were performed. There
was no postoperative monitoring protocol, though prob-
lems such as difﬁculty with venous return, inadequate
outﬂow, high venous pressure, and prolonged cannulation
site bleeding led to physical and ultrasound examinations,
followed by an appropriate intervention. The study was
approved by the ethics committee of the hospital. All
patients provided written informed consent.
Operative and cannulation techniques. Under local
anesthesia with 1% lidocaine, a 10 to 15 cm hockey stick-
shaped continuous skin incision was made on the medial
aspect of the upper arm away from the BA to the ante-
cubital fossa (Fig 1, A). Such extensive exposure was
considered necessary in order to have a sufﬁcient length of
the BA for cannulation. After creation of a skin ﬂap with
subcutaneous fatty tissue below the dermis (Fig 1, B), the
BA was identiﬁed by dividing the ﬁbrous extensions of thebiceps tendon, then opening the sheath surrounding the
neurovascular bundle. The BA was dissected away from the
adjacent veins and nerves, especially the median nerve, by
ligating all side branches with 3-0 or 4-0 silk ties, and
isolated. Subcutaneous tissue beneath the BA was closed
with absorbable interrupted sutures, the BA was mobilized
to the ventral aspect of the upper arm (Fig 1, C), and the
skin ﬂap was closed with interrupted sutures (Fig 1, D). It
should be emphasized that thickness of the skin ﬂap is a key
with this procedure for easy cannulation and hemostasis, as
skin erosion may occur with a thin ﬂap, and cannulation
will be difﬁcult if the ﬂap is too thick. Fig 2 shows a typical
postoperative ultrasound image. The superﬁcialized BA
was cannulated using a 16- or 17-gauge needle (Supercath
CLS; Medikit Co, Ltd, Tokyo, Japan; Fig 3) after the skin
wound was completely healed (ie, 2 or more weeks after
the procedure, which may require more than 1 month in
frail patients, such as those affected by malnutrition). This
was then used as an outﬂow route after meeting the he-
modialysis requirements of the nephrologist at the indi-
vidual dialysis unit (150-250 mL/minute for 4 hours, three
times a week), with any vein in an upper extremity utilized
for blood return, including the hand if sites in the arm were
not accessible. Venous cannulation was performed using a
16- or 17-gauge needle. Fig 4 depicts several representative
views of cannulation of the superﬁcialized BA as well as the
returning veins. As for cannulation of the superﬁcialized
BA, we paid attention to certain key points to minimize
complications. First, at the initial cannulation, the puncture
attempt was limited to a single attempt, because multiple
Fig 2. Representative duplex ultrasound image of a superﬁcialized brachial artery (BA) obtained 3 months after the
procedure showing appropriate subcutaneous tissue thickness.
Fig 3. Cannulation system (16 G). A,Metallic needle encased in a
catheter with side holes. B, Magniﬁed view of catheter tip. Note
the side holes to enable efﬁcient blood drawing.
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might lead to pseudoaneurysm formation. The hemostasis
procedure used was the same as that for sheath removal
after an endovascular procedure. After needle withdrawal,
it is important to compress the BA ﬁrmly for 5 to 10 mi-
nutes and then gradually reduce the pressure for another
10 minutes. Since the BA is located just beneath the skin, it
was not a problem to correctly compress the puncture site.
By repeated cannulation and hemostasis, the BA wall
became thick and stabilized, which enabled easier cannu-
lation and hemostasis, though modest aneurysmal changes
were seen in most cases.
Statistical analysis. Values are expressed as the
mean 6 standard error or observed range. The Kaplan-
Meier method was used to calculate cumulative patency
rate and survival rate. Censored end points were death, loss
to follow-up, and access survival at the last examination.
Data were analyzed using the Excel (Microsoft, Redmond,
Wash) and SPSS (SPSS Inc, Chicago, Ill) software
packages.
RESULTS
From January 2005 to December 2008, 24 superﬁcial-
ized BAs were created in 24 patients, which represents2.3% of all VA procedures for hemodialysis performed at
our institution during that period. Demographic data are
shown in the Table. The mean patient age was 69 years
(range, 39-84 years), of whom 11 (46%) were women
and eight (33%) were diabetic. Mean body mass index
was 19.1 (range, 14.6-22.3), and there were no obese pa-
tients in this cohort. The mean duration of hemodialysis
treatment before the procedure was 8.6 years (range,
0.1-30 years), and none of the patients underwent perito-
neal dialysis prior to the procedure. All patients were
followed for a mean period of 28 months (range,
1-77 months). Superﬁcialization of the BA was performed
only in selected cases, as described above. In 13 patients
(54%), the indication was severe congestive heart failure
(New York Heart Association class III-IV, ejection fraction
[EF] <40%). In three patients (13%), superﬁcial veins were
available for AVF creation, though all patients suffered
from advanced upper extremity arterial disease or ischemic
steal syndrome requiring AVF closure. Two patients (8%)
had a functioning AVF, but required AVF closure because
of severe venous hypertension with central vein occlusion.
Repeated AVF and AVG thrombosis due to heparin-
induced thrombocytopenia was an indication for this pro-
cedure in one patient (4%). In addition, ﬁve patients
(21%) who refused prosthetic graft implantation were
indicated.
All patients tolerated the procedure well, and the mean
operative time was 49 minutes (range, 25-85 minutes).
The superﬁcialized BA was punctured uneventfully without
signiﬁcant pain and provided a ﬂow rate of 150 to
250 mL/minute, thus meeting the hemodialysis require-
ment of each patient. Two patients recovered from heart
failure in whom an AVG was successfully created after 5
and 29 months, respectively. During the late postoperative
period, aneurysmal change was seen in most cases because
of repeated punctures in the short segment of the BA,
though the superﬁcialized BA remained functioning by
changing the puncture site (Fig 4, B). As for serious com-
plications, one patient had an infected pseudoaneurysm
rupture, which necessitated BA ligation after 39 months,
two patients required an aneurysmectomy with reconstruc-
tion of the BA after 30 and 72 months, respectively, and
occlusion of the superﬁcialized BA was observed in one
Fig 4. Representative views of superﬁcialized brachial artery (BA) in use. A, The returning vein is the cephalic vein in
the right upper arm. Modest aneurysmal changes of the superﬁcialized BA can be seen. B, Both the vein and artery were
cannulated with a 16-G needle (ﬂow rate, 250 mL/minute; venous pressure, 100 mm Hg). This vascular access (VA)
remained functioning for more than 4 years. C, No superﬁcial veins were available and only the cephalic vein at the
shoulder was used as a returning vein. D, Magniﬁed view of returning vein (17-G needle; ﬂow rate, 200 mL/minute;
venous pressure, 100 mm Hg). E, Magniﬁed view of superﬁcialized BA. Modest aneurysmal changes were seen after
3 years of repeated cannulation (17-G needle; ﬂow rate, 200 mL/minute).
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Table. Baseline demographic and clinical data for 24
cases of superﬁcialization of the brachial artery (BA)
No. of patients 24
Mean age, years (range) 69 (39-84)
Mean duration of hemodialysis, years (range) 8.6 (0.1-30)
Gender (male/female) 13/11
Body mass index (range) 19.1 (14.6-22.3)
Cause of end-stage renal disease
Diabetes mellitus 8 (33%)
Chronic glomerulonephritis 5 (21%)
Hypertensive nephrosclerosis 2 (8%)
Unknown 9 (38%)
Comorbid conditions
Heart failure 13 (54%)
Peripheral artery disease 10 (42%)
Coronary artery disease 8 (33%)
Hypercoagulability 1 (4%) Fig 5. Cumulative functional vascular access (VA) patency rate for
24 superﬁcialized brachial arteries (BAs) in the present study.
*Standard error exceeded 10% at 20 months.
Fig 6. Cumulative survival rate for the 24 patients. *Standard
error exceeded 10% at 16 months.
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hand ischemia developed. No other complications such as
interrupted blood ﬂow to the hand, remote infection, or
forearm compartment syndromes were observed. Another
major complication was complete lack of a vein for return
of blood, which was seen in ﬁve patients, including three
who initially refused implantation of a prosthetic graft.
Those three patients eventually accepted a prosthetic graft,
while the other two underwent implantation of a central
venous catheter. In contrast, if the patient had a robust
vein (>2.5 mm), that was considered to be acceptable as
a long-term return site, as the vein proximal to the access
site will become dilated over time (Fig 4, A).
The rates of patency of the superﬁcialized BA as a func-
tioning VA were 95% and 66% after 1 and 3 years, respec-
tively (Fig 5). Overall survival for all patients was 74% at
12 months and 60% at 24 months (Fig 6). During the
study period, 14 patients (58%) died at a mean 20 months
(range, 1.0 to 44 months) after the procedure. None of
these deaths were related to the VA, and the superﬁcialized
BA remained patent as a functioning VA in all cases. The
causes of death were heart failure (n ¼ 4), sepsis due to
pneumonia (n ¼ 3), and unknown (n ¼ 7).
DISCUSSION
The present results indicate that superﬁcialization of
the BA is a durable alternative VA that has acceptable
complication rates in selected Japanese hemodialysis pa-
tients. The advantages of BA superﬁcialization include
simplicity and safety, quick use of the access (2 to 3 weeks
after surgery), no maturation time, no recirculation, and
lack of cardiac overload, thus indicating its theoretic suit-
ability for patients with severe heart failure, as long as a
robust return venous site is available. When there is a
need to ligate a functioning AVF, such as in patients with
venous hypertension with central vein occlusion or
ischemic steal syndrome, this VA can be applied for such
difﬁcult cases. Venous hypertension is associated with a
high ﬂow rate (>3000 mL/minute of BA ﬂow), and
both arteries and veins are well dilated in this condition.Once superﬁcialization of the BA is created after ligating
the AVF, the superﬁcialized BA as well as returning vein
are easily accessed. The venous vascular bed is adequate
for blood return and venous pressure should be less than
100 mm Hg at 200 to 250 mL/minute. Although our
experience is limited to only two cases, we believe that
venous pressure will not rise signiﬁcantly even if the ﬂow
rate is greater than 400 mL/minute, because that is far
less than that with an AVF in a patient with venous
hypertension.
The patency rate of the superﬁcialized BA as a func-
tioning VA without revision in the present patients was
satisfactory (95% at 1 year, 66% at 3 years) after considering
their comorbid conditions. Since this autogenous shuntless
VA has no maturation problems and stenosis of the BA
over time is rare, postoperative surveillance is unnecessary,
which contributes to lower cost as compared with a pros-
thetic graft or central venous catheter.9
Use of an artery as permanent VA for hemodialysis is
not a new concept. Brittinger et al ﬁrst reported a proce-
dure to subcutaneously ﬁx a superﬁcial FA for a needle
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tery has also been reported.11,12 In Japan, superﬁcialization
of the BA was originally developed as a backup method for
a malfunctioning VA, while it is now used permanently in
2% to 3% of hemodialysis patients. Yasunaga et al presented
the ﬁrst English language report in Japan regarding super-
ﬁcialization of either the BA or FA in 1995.13 Their main
indications were hemodialysis patients with inappropriate
veins, and frequent AVF or AVG failure. They reported a
patency rate of superﬁcially repositioned arteries of 87%
at 3 years and mean survival time of 65 months. In our
superﬁcialized BA-provided series, 13 of the 24 procedures
were performed in patients with severe heart failure to
avoid cardiac overload, and the overall patient survival
rate was limited to 60% at 24 months. In the present study,
ﬁve were indicated for superﬁcialization of the BA because
of patient refusal of prosthetic graft implantation. This may
occur only rarely in other countries. It is possible that Jap-
anese hemodialysis patients are more likely to be concerned
about the various complications associated with an AVG as
compared with an AVF, which is being used in over 90% of
hemodialysis patients in Japan. Superﬁcialization of the BA
was indicated for one patient with heparin-induced throm-
bocytopenia who had a history of multiple occurrences of
AVF and AVG thrombotic occlusion, even though a direct
thrombin inhibitor was administrated. Although a superﬁ-
cialized BA functioned as the drawing site for more than
4 years in this case, further study to conﬁrm whether this
type of VA is effective for patients with heparin-induced
thrombocytopenia is needed.
Although cardiovascular disease including heart failure
is highly prevalent and the leading cause of death in dialysis
patients,14-17 very few therapeutic options are available to
prevent and treat its progression. Therefore, intractable
clinical heart failure as an adverse effect from the VA should
be considered as a possible contributing factor, even
though the exact role of the VA in this morbidity is unclear.
Heart failure is a complex clinical syndrome resulting from
any structural or functional cardiac disorder that impairs
the ability of the ventricle to ﬁll with or eject blood. An
EF <40% was adopted as the cutoff to deﬁne systolic
dysfunction, though other factors such as diastolic dysfunc-
tion, cardiomyopathy, and ischemic heart disease should be
considered prior to a diagnosis of heart failure. The causes
of congestive heart failure in the present patients were het-
erogeneous, as some had EF <30%, while others had an EF
of 40% but with concomitant severe valvular heart disease
or cardiomyopathy also observed. All these heart failure
cases were diagnosed as New York Heart Association func-
tional class III-IV. A tunneled central venous catheter is
generally used in patients with severe heart disease for
long-term dialysis. The percentage of patients using a cath-
eter has increased in most countries in recent years, even
though tunneled central venous catheters are prone to
infection, stenosis, and thrombosis of the central veins,
and are not considered to represent an acceptable long-
term alternative.2,18 These issues further support the role
of the present VA procedure. On the other hand, ourshuntless VA has certain drawbacks, because it requires
recurrent cannulation of the short segment of the BA,
and the veins available for return are limited, which can
lead to substantial complications, such as prolonged punc-
ture site bleeding, arterial aneurysm, pseudoaneurysm, ste-
nosis, and thrombosis.
In our series, we encountered three cases with
enlarging aneurysms that required surgical repair, including
rupture of an infected pseudoaneurysm. All of these com-
plications were associated with inappropriate hemostasis.
Special attention should be paid at the initial cannulation,
as previously described. Multiple attempts at an initial can-
nulation may lead to inappropriate hemostasis as well as
pseudoaneurysm formation, though no such complications
were observed in the present patients. The superﬁcialized
BA gradually stabilized, and modest aneurysmal changes
were seen over time in most of our cases, while serious
complications were rare. Close cooperation with nephrolo-
gists and the dialysis staff with the unique characteristics of
this particular VA in mind is also essential to prevent
serious complications. Since the superﬁcialized BA will
not become enhanced over time, the recommended diam-
eter is greater than 4 mm, and the procedure should not be
indicated if that diameter is less than 3 mm because of dif-
ﬁculty with cannulation. In addition, a unique VA cannula-
tion system is available for use in Japan, in which the
metallic needle is encased in a catheter with multiple side
holes. This needle is soft and ﬂexible, thus it might be
less traumatic to the vessel wall and may have contributed
to our favorable outcomes. Occlusion of the BA may lead
to distal ischemia and requires immediate salvage. In our
patients, we noted that occlusion or ligation of the BA
was well tolerated because of sufﬁcient collateral ﬂow.
However, arterial reconstruction may be necessary in pa-
tients with advanced peripheral arterial disease. In cases
with complete lack of a returning vein, this VA should be
abandoned and a tunneled central venous catheter is indi-
cated. Those cases are rare exceptions in Japan, with only
2% of dialysis patients using such a catheter, a striking dif-
ference as compared with the United States, Canada, and
the United Kingdom, where catheter use is at least 23%.7
Although the reasons for this difference are not clear, we
postulate that they are related, at least in part, to the prev-
alence and degree of obesity. In our series, none of the pa-
tients were obese, and the mean body mass index was 19.1,
which might account for our high success rate of the super-
ﬁcialized BA as a functioning VA and low rate of central
venous catheter usage. We also speculate that dialysis is
offered to patients in the United States with more
advanced age and comorbidity as compared with Japanese
dialysis patients.
In the present study, the superﬁcialized BA provided
sufﬁcient dialysis blood ﬂow (150-250 mL/minute) in all
cases, though it should be noted that the median blood
ﬂow required at initiation of hemodialysis varies widely
among various countries (300, 250, 200, and 160 mL/
minute in the United States, the United Kingdom, Ger-
many, and Japan, respectively).19 It has been reported
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300 mL/minute, thus this VA may be applicable in other
countries in addition to Japan.20 A number of new ap-
proaches for autogenous VA for patients with a difﬁcult
access extremity, including basilic vein transposition,21
femoral vein transposition,22,23 and brachial vein transposi-
tion,24 have been reported. However, we consider that
these procedures are extensive as compared with the pre-
sent method and can be performed only in individuals
without signiﬁcant comorbidity. Therefore, we believe
that the utility of our method for use of a superﬁcialized
BA as a VA can be extended worldwide for treatment of
appropriately selected patients.
Limitations of this study include its retrospective
design and data obtained from a single institute. Diagnosis
of heart failure in dialysis patients can be difﬁcult, because it
may coexist with volume overload. Also, patient selection
may be biased by the preference of the VA surgeon, patient
comorbidities, and other unmeasured yet potentially
important confounders.
CONCLUSIONS
Superﬁcialization of the BA was found to be a simple
and safe technique, with acceptable durability and rate of
complications in selected Japanese hemodialysis patients.
We consider that this shuntless VA permits adequate blood
ﬂow and has theoretical advantages for some patients,
particularly those with impaired cardiac function, though
the availability of a return vein is a prerequisite for a func-
tioning VA.
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1392 Nakamura et al May 2014DISCUSSIONDr Nicolas A. Nelken (Honolulu, Hawaii). One of the great
things about reviewing a paper from another country is trying to
make sense of the differences in practice. Two to three percent
of Japanese dialysis patients undergo a procedure most of us
have never even heard of. That’s almost 9000 patients.
Are the differences historical, cultural, or physiological? His-
torical? Is this just a geographical product of the “see one, do
one, teach one” tradition in spite of worldwide instantaneous ac-
cess to information? Is it cultural? From the patient point of
view, it is highly unlikely that any patient would demand this
over a graft in my practice. Or from the doctor’s point of view,
it is unlikely that we would choose this procedure for an ejection
fraction of 40%, might be more likely at 30%, and would be a
good idea to explore at 25%. Or is it physiologic differences be-
tween populations? I had to laugh when I read that the average
body mass index (BMI) of Dr Nakamura’s patients was 19.1.
We don’t even operate in the same universe! That’s not Japan.
that’s Heaven!
So I think this new procedure shows promise, but. how do
we make sense of this for ourselves?
Let’s look at the individual indications from least likely to be
helpful to the most. I think it makes little sense to use this for pa-
tients with poor peripheral venous anatomy. If you can’t ﬁnd a vein
for a ﬁstula, how will you ﬁnd a vein for outﬂow? It makes a little
more sense to explore for those patients with congestive heart fail-
ure. I’m just not sure of the threshold. I’m yet more interested for
patients with central venous occlusion. The most interesting indi-
cation for me is for steal syndrome. Since we’ve already failed and
endangered the nondominant hand, it is good to know we have
another procedure to try before risking and jumping to the domi-
nant hand.
So, with this in mind, I have the following questions to help
resolve this: (1) At what BMI should we forget about it? Or is
this a depth issue that can be measured with ultrasound? (2)
How do patients tolerate the outﬂow during 4-hour dialysis runs
when they have central obstruction? (3) And ﬁnally, in my opinion,
the weak link in dialysis access care in America is at the technician
level. With a 4-year arterial failure rate of 40%, please excuse me
from being a little nervous. What can you tell me to allay my fears?
Dr Takashi Nakamura. Dr Nelken, thank you for your
thoughtful comments.
I would like to address your questions about BMI and the
depth of the artery. Data from the OECD (Organization for Eco-
nomic Cooperation and Development) show that individuals witha BMI over 25, which is considered to be obese, comprise only 3%
of the population in Japan as compared to 35% in the U.S. There-
fore, even though our cohort is thin, it is not an unusual represen-
tation in Japan.
Prior to surgery, we estimate the depth and elasticity of the
brachial artery in a physical examination and then perform an ultra-
sound examination with a tourniquet placed to verify the existence
of robust veins for return sites. In addition, we also evaluate the
brachial artery for diameter, degree of atherosclerosis, degree of
calciﬁcation, and anatomical variations, such as highly bifurcated
type or not and depth from the skin. We have not determined
exact criteria for depth because we rarely encounter obese patients.
To apply our method in obese patients, I would recommend a
lipectomy with a longer incision, which might create enough
length for cannulation, though I have not attempted that.
As for venous hypertension with central vein occlusion, it is
basically associated with a high blood ﬂow state, over 3000 to
4000 mL/min, which eventually requires banding or ligation of
the arteriovenous ﬁstula. However, if superﬁcialization of the
brachial artery is performed, the dilated artery as well as the dilated
returning vein can still be used as access sites. During a dialysis ses-
sion, average blood ﬂow is kept lower than 250 mL/min in Japan,
which is far less than with a patent arteriovenous ﬁstula. In fact,
venous pressure is constantly lower than 150 mm Hg; thus, central
venous occlusion is not a problem. Furthermore, even if blood
ﬂow is increased to 400 mL/min, I don’t think that venous hyper-
tension during a dialysis session will be a problem.
Close cooperation among the attending nephrologists and
dialysis staff regarding the unique characteristics of this particular
vascular access (VA) is essential to prevent serious complications.
Local hematoma formation or a minor infection at the site of punc-
ture related to inappropriate hemostasis by inexperienced
personnel should be avoided. I am sure that you will understand
how our method works after you attempt it. In fact, this VA has
been utilized in appropriately selected Japanese hemodialysis pa-
tients for more than 20 years with very satisfactory results.
Finally, a tunneled central venous catheter is generally used in
patients with severe heart disease for long-term dialysis. The per-
centage of patients using a catheter has increased in most countries
in recent years, even though tunneled central venous catheters are
prone to infection, stenosis, and thrombosis of the central veins,
and are not considered to represent an acceptable long-term alter-
native. Therefore, I recommend that this VA be considered before
indwelling central venous catheters.
